New York, New York 10032

  • Myelodysplastic/Myeloproliferative Neoplasms


RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

Study summary:

OBJECTIVES: - Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy. - Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen. OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months. PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.


DISEASE CHARACTERISTICS: - Diagnosis of one of the following: - Chronic myelogenous leukemia - Philadelphia chromosome-positive OR - Molecular evidence of bcr/abl gene rearrangement - Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia - Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities - Multiple myeloma - Hereditary immunodeficiency disorders - Confirmed by immunologic determination - Sickle cell anemia or beta-thalassemia - Confirmed by hemoglobin electrophoresis - Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy) - Confirmed by metabolic testing - Other non-malignant conditions - Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation PATIENT CHARACTERISTICS: Age: - 65 and under Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified



Primary Contact:

Principal Investigator
David G. Savage, MD
Herbert Irving Comprehensive Cancer Center

Backup Contact:


Location Contact:

New York, New York 10032
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.